About 12% of people in the United States are currently living with herpes simplex virus type 2 (HSV-2) genital herpes. Moderna is sponsoring the Vantage Trial, a clinical trial looking at the safety and immune response of an investigational vaccine to potentially treat HSV-2. Your participation may help advance research of an investigational treatment option for HSV-2—one that aims to treat genital herpes and relieve the burden of daily medication.
If you are living with HSV-2, you may be eligible to join. To learn more, contact the UAB Sexual Health Research Clinic at 205-934-8166.
December 18, 2023
Seeking Adults 18 to 55 Years of Age for Clinical Trial
Published in
Clinical Trials